<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Can J Infect Dis Med Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Can J Infect Dis Med Microbiol</journal-id><journal-id journal-id-type="publisher-id">CJIDMM</journal-id><journal-title-group><journal-title>The Canadian Journal of Infectious Diseases &#x00026; Medical Microbiology = Journal Canadien des Maladies Infectieuses et de la Microbiologie M&#x000e9;dicale</journal-title></journal-title-group><issn pub-type="ppub">1712-9532</issn><issn pub-type="epub">1918-1493</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4983356</article-id><article-id pub-id-type="doi">10.1155/2016/6403928</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Fluoroquinolone Resistance among Clonal Complex 1 Group B<italic> Streptococcus</italic> Strains</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3103-5823</contrib-id><name><surname>Neemuchwala</surname><given-names>Alefiya</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Teatero</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Samir N.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9553-3798</contrib-id><name><surname>Fittipaldi</surname><given-names>Nahuel</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Public Health Ontario Laboratory, Toronto, ON, Canada M5G 1M1</aff><aff id="I2"><sup>2</sup>Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada M5S 1A1</aff><author-notes><corresp id="cor1">*Nahuel Fittipaldi: <email>nahuel.fittipaldi@oahpp.ca</email></corresp><fn fn-type="other"><p>Academic Editor: Jorge Garbino</p></fn></author-notes><pub-date pub-type="ppub"><year>2016</year></pub-date><pub-date pub-type="epub"><day>31</day><month>7</month><year>2016</year></pub-date><volume>2016</volume><elocation-id>6403928</elocation-id><history><date date-type="received"><day>14</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>14</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Alefiya Neemuchwala et al.</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Fluoroquinolone resistance in group B<italic> Streptococcus</italic> is increasingly being reported worldwide. Here, we correlated fluoroquinolone resistance with mutations in<italic> gyrA</italic>,<italic> gyrB</italic>,<italic> parC</italic>, and<italic> parE</italic> genes, identified by mining whole-genome sequencing (WGS) data of 190 clonal complex 1 group B<italic> Streptococcus</italic> strains recovered from patients with invasive diseases in North America. We report a high prevalence of fluoroquinolone resistance (12%) among GBS strains in our collection. Our approach is the first step towards accurate prediction of fluoroquinolone resistance from WGS data in this opportunistic pathogen.</p></abstract><funding-group><award-group><funding-source>Public Health Ontario</funding-source></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Group B<italic> Streptococcus</italic> (GBS) causes neonatal sepsis and meningitis and is increasingly recognized as the causative agent of opportunistic infections in adults, particularly the elderly and those immunocompromised [<xref rid="B1" ref-type="bibr">1</xref>]. Ten GBS serotypes (Ia, Ib, and II to IX) have been described [<xref rid="B2" ref-type="bibr">2</xref>]. Historically, serotype V and, more recently, serotype IV have been associated with adult invasive GBS disease in North America [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. Most serotype V strains isolated in this continent from the blood of adult patients with invasive GBS disease belonged to the multilocus sequence typing (MLST) sequence type (ST) 1 [<xref rid="B3" ref-type="bibr">3</xref>], whereas North American serotype IV isolates from adult invasive infections predominantly belonged to ST459 [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. These two STs are grouped in MLST clonal complex (CC) 1. Although penicillin continues to be the first antimicrobial choice for treatment, recent reports have described decreased susceptibility in some GBS isolates [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Resistance to other agents such as erythromycin, clindamycin, and tetracycline is also common among invasive GBS strains [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. Fluoroquinolones are another important antibiotic class commonly used in adults to treat infections [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>]. Resistance to fluoroquinolones among GBS strains has also been observed globally [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>].</p><p>Phenotypic assays are the method of choice for determining drug susceptibility. However, nucleic acid-based tests detecting the presence of resistance genes and/or mutations in key genes leading to resistance have long proven useful for resistance prediction and elucidation of resistance mechanisms [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B13" ref-type="bibr">13</xref>]. In recent years, nucleic acid-based detection systems have been impacted by the advent of relatively inexpensive whole-genome sequencing (WGS). Several bioinformatics tools permitting prediction of antimicrobial resistance encoded by acquired genes (i.e., those genes which can be either present in or absent from the genome of any particular strain) have been developed [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>]. Molecular prediction of fluoroquinolone resistance requires amplification and sequencing of genes<italic> parC</italic>,<italic> parE</italic>,<italic> gyrA</italic>, and<italic> gyrB</italic> [<xref rid="B15" ref-type="bibr">15</xref>]. Acquisition of mutation information by direct inspection of WGS short-read data obtained using the most common Illumina sequencing technology is challenging, as these genes are present in all strains, and no consistent database of known mutations is available.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Bacterial Strains</title><p>We tested 190 clonal complex 1 (85 serotype V ST1 and 105 serotype IV ST459) isolates that were recovered from patients with invasive infections in Canada as part of laboratory surveillance from 2009 to 2013 (<xref ref-type="table" rid="tab1">Table 1</xref>). These isolates have been described earlier [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. Isolates were grown on Columbia Blood agar at 37&#x000b0;C in the presence of 5% CO<sub>2</sub>.</p></sec><sec id="sec2.2"><title>2.2. Antibiotic Susceptibility Testing</title><p>Minimum inhibitory concentrations (MICs) for levofloxacin, ciprofloxacin, and norfloxacin were determined using the agar dilution method. The levofloxacin MIC results were interpreted as per Clinical and Laboratory Standards Institute (CLSI) guidelines [<xref rid="B16" ref-type="bibr">16</xref>], whereas norfloxacin and ciprofloxacin MIC results were interpreted based on previous studies [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B17" ref-type="bibr">17</xref>].</p></sec><sec id="sec2.3"><title>2.3. Whole-Genome Sequencing and Phylogenetic Analysis</title><p>We used paired-end (150&#x02009;nt + 150&#x02009;nt or 101&#x02009;nt + 101&#x02009;nt) reads obtained using Illumina MiSeq or HiSeq instruments. NCBI Sequence-Read Archive accession numbers for WGS have been reported previously [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. To evaluate the feasibility of predicting resistance to fluoroquinolones in GBS directly from short-read genome data, we first searched the literature for articles reporting mutations in genes<italic> parC</italic>,<italic> parE</italic>,<italic> gyrA</italic>, and<italic> gyrB </italic>that have been associated with fluoroquinolone resistance and created a working database of known mutations conferring resistance to this antimicrobial class. Next, we interrogated the 190 GBS genomes in our collection for mutations in<italic> parC</italic>,<italic> parE</italic>,<italic> gyrA</italic>, and<italic> gyrB</italic>. Briefly, we aligned the Illumina short-reads against reference strains (strain NGBS061 for ST459 isolates and strain SGBS001 for ST1 isolates, GenBank accession numbers CP007631.2 and CP010867.2, resp.) and identified polymorphisms using the variant ascertainment algorithm (VAAL) [<xref rid="B18" ref-type="bibr">18</xref>]. We also investigated the presence of genes encoding putative efflux pumps which might mediate fluoroquinolone resistance. To this end, we first generated<italic> de novo</italic> genome assemblies for all 190 strains using the A5 pipeline [<xref rid="B19" ref-type="bibr">19</xref>], followed by BLAST comparisons using the nucleotide sequences of known efflux pumps as queries.</p></sec></sec><sec id="sec3"><title>3. Results</title><p>Previous studies have shown that CC1 GBS is a group of organisms predominantly associated with invasive diseases in adults [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. Most of the isolates used here were recovered from the blood of adults and older adult patients (<xref ref-type="table" rid="tab1">Table 1</xref>). Previous studies which evaluated in part the 190 GBS isolates in our collection reported highly prevalent resistance to erythromycin, clindamycin, and tetracycline [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. Macrolide resistance was mostly attributed to the presence of<italic> ermB</italic>,<italic> ermTR</italic>, and/or other genes, while tetracycline resistance was associated with<italic> tetM</italic> genes [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. Analysis of short-read WGS data revealed that 22 CC1 isolates had nonsynonymous single-nucleotide polymorphisms (SNPs) in genes<italic> parC</italic>,<italic> parE</italic>,<italic> gyrA</italic>, and<italic> gyrB</italic> (<xref ref-type="table" rid="tab2">Table 2</xref>). All strains with a wild-type (WT)<italic> parC</italic>,<italic> parE</italic>,<italic> gyrA</italic>, and<italic> gyrB</italic> allele (defined as the DNA sequence of the allele found in the reference strain genome) were susceptible to levofloxacin (MIC &#x0003c; 1&#x02009;mg/L), norfloxacin (MIC &#x0003c; 4&#x02009;mg/L), and ciprofloxacin (MIC &#x0003c; 0.125&#x02009;mg/L). Mutations in<italic> parC</italic> predominated among GBS strains exhibiting fluoroquinolone resistance. The predicted amino acid (aa) substitutions at positions 79 and 83 of ParC correlated with increased MICs to ciprofloxacin and levofloxacin. Four of the ST1 isolates with aa substitutions in ParC also had aa substitutions in GyrA, at aa positions 85 (<italic>n</italic> = 3) and 81 (<italic>n</italic> = 1). All of these isolates exhibited very high MICs to fluoroquinolones (<xref ref-type="table" rid="tab2">Table 2</xref>). Thus, our data supports the previous observation that single point mutations in specific aa residues of ParC are sufficient to cause high-level resistance against norfloxacin and ciprofloxacin and to reduce susceptibility against levofloxacin [<xref rid="B8" ref-type="bibr">8</xref>]. However, the presence of mutations in both<italic> parC</italic> and<italic> gyrA</italic> resulted in very high level of resistance (MICs &#x0003e; 32&#x02009;mg/L) of the strains to all fluoroquinolones including levofloxacin. We found that a single point substitution in ParC (S79F) in 3 different isolates leads to high level resistance (MIC &#x0003e; 32&#x02009;mg/L) to norfloxacin and intermediate resistance to ciprofloxacin (MIC 4&#x02009;mg/L). Thus, we speculate that aa substitution at residue 79 impacts more severely the binding of fluoroquinolones than substitutions at aa position 83. None of the single point mutations at aa position 83 of ParC led to the development of high level resistance to levofloxacin and ciprofloxacin. In addition, none of the other single mutations in the<italic> gyrA</italic> gene that we identified led to fluoroquinolone resistance<italic> per se</italic>. Similarly, most mutations in<italic> gyrB </italic>did not lead to development of resistance. However, a single aa substitution (E224G) in GyrB resulted in an MIC of 16&#x02009;mg/L for norfloxacin in a single ST1 isolate. We also identified several mutations in the<italic> parE</italic> gene. We discovered that a Q444K substitution in ParE led to ciprofloxacin resistance. Another substitution (R449S) in ParE also led to low level resistance to norfloxacin. Finally, we identified one GBS strain without mutations in any of<italic> parC</italic>,<italic> parE</italic>,<italic> gyrA</italic>, and<italic> gyrB </italic>genes which was highly resistant to norfloxacin (MIC &#x0003e; 32&#x02009;mg/L) and ciprofloxacin (MIC = 8&#x02009;mg/L) but susceptible to levofloxacin. BLAST analysis of the genome of this strain identified the presence of a gene that is very similar to<italic> S. pneumoniae pmr</italic>, a known norfloxacin efflux pump [<xref rid="B20" ref-type="bibr">20</xref>]. BLAST comparisons did not identify this efflux pump in any of the other 189 GBS strains.</p></sec><sec id="sec4"><title>4. Discussion</title><p>GBS causes neonatal diseases and is also responsible for an increasing number of invasive infections in adults. The serotype V ST1 and the serotype IV ST459 GBS isolates included in this study represent two emerging GBS groups associated with adult invasive GBS infections in North America. Previous work has shown that rates of resistance to tetracyclines, erythromycin, and clindamycin among GBS strains in general and in strains included in our collection in particular are relatively high [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. Here, we report a relatively high rate (12.4%) of fluoroquinolone nonsusceptible isolates and high resistance to levofloxacin (2%) among serotypes V and IV CC1 GBS strains causing adult invasive diseases. A previous investigation described low (0.7%) fluoroquinolone resistance rates among <italic>&#x003b2;</italic>-hemolytic streptococci in North America [<xref rid="B11" ref-type="bibr">11</xref>], but that study did not discriminate among GBS subtypes. On the other hand, high rates of fluoroquinolone resistance have been observed in GBS isolates (mostly serotype III or Ib ST19 strains) from Japan (18.4%), Taiwan (4.8%), and China (37.5%) [<xref rid="B12" ref-type="bibr">12</xref>]. Although resistance to fluoroquinolones appears to be on the rise in Canada, the rates reported here are lower than those in these Asian countries, which may be reflective of differences in antimicrobial usage practice in these different geographies. Interestingly, recent reports have also described reduced susceptibility to penicillin mediated by mutations in penicillin-binding protein PBP2X among some fluoroquinolone-resistant GBS from Japan [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. However, we did not observe mutations in PBP2X among fluoroquinolone-resistant GBS isolates in our collection.</p><p>We found that high level of fluoroquinolone resistance correlated with mutations in both<italic> parC</italic> and<italic> gyrA</italic> genes. Varying levels of resistance were observed when single amino acid substitutions occurred in either<italic> parC</italic>,<italic> gyrA</italic>,<italic> parE</italic>, or<italic> gyrB</italic>. Resistance to fluoroquinolones can arise from mutations in the so-called quinolone resistance determining region (QRDR) of<italic> parC</italic>,<italic> parE</italic>,<italic> gyrA</italic>, and<italic> gyrB</italic> genes but can also result from protection of quinolone binding to<italic> gyrA</italic> and topoisomerase and/or the action of efflux pumps, which are sometimes encoded in extra chromosomal genetic elements [<xref rid="B15" ref-type="bibr">15</xref>]. Interestingly, although norfloxacin is no longer used in treatment, we also identified that a single strain with no mutations in these four genes but which was resistant to norfloxacin possessed a copy of a gene encoding a known efflux pump described in other species [<xref rid="B20" ref-type="bibr">20</xref>]. A recent study from South Korea also reported norfloxacin resistance in GBS isolates mediated by the action of efflux pumps [<xref rid="B17" ref-type="bibr">17</xref>].</p><p>Several tools permitting rapid detection of antimicrobial resistance encoded by acquired genes (i.e., those which can be either present in or absent from the genome of any particular strain) have been developed [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>]. Our findings suggest that, provided a consistent database of known mutations, fluoroquinolone resistance can be predicted from WGS data with relative ease. WGS of hundreds of bacterial organisms at diagnostic and public health laboratories is now a reality. Working towards the development of curated databases linking genotypic information, such as the mutations described here, with phenotypic results is crucial to achieve the goal of predicting antimicrobial resistance from WGS data rapidly and accurately.</p><p>One limitation of our study is that our collection of organisms is temporally restricted (isolates recovered 2009&#x02013;2013), thus hampering investigations into the evolution of mutations associated with fluoroquinolone resistance. However, we identified that most mutations related to fluoroquinolone resistance appeared only once, consistent with highly clonal ST1 and ST459 GBS organisms that may be undergoing continuous clonal expansion [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. We also did not observe any conclusive evidence of strain clustering based on mutations in genes associated with fluoroquinolone resistance nor any obvious temporal associations (data not shown). Another limitation is that we do not know whether the patients from whom isolates were recovered had been prescribed fluoroquinolones. However, even if fluoroquinolones might not be commonly used to treat GBS adult infections in Canada, it can be speculated that increased fluoroquinolone utilization in treatment of respiratory and urinary tract infections may be contributing to selection of resistant strains among the commensal GBS population in adults [<xref rid="B9" ref-type="bibr">9</xref>]. Interrogating WGS data to identify mutations leading to resistance in GBS is challenging as there is no database of known mutations. Susceptibility testing is the gold standard for identifying resistance among clinical strains. Our study provides further evidence on linking resistance to mutations in<italic> parC</italic>,<italic> parE</italic>,<italic> gyrA</italic>, and<italic> gyrB</italic> genes and demonstrates the feasibility of applying WGS data to identify antimicrobial resistance for such genes.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank William Tennant and staff at Public Health Ontario Media Department for preparing culture media used in this study. This work was supported by Public Health Ontario.</p></ack><sec><title>Competing Interests</title><p>The authors declare that there are no competing interests regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farley</surname><given-names>M. M.</given-names></name><name><surname>Harvey</surname><given-names>R. C.</given-names></name><name><surname>Stull</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A population-based assessment of invasive disease due to group B <italic>Streptococcus</italic> in nonpregnant adults</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1993</year><volume>328</volume><issue>25</issue><fpage>1807</fpage><lpage>1811</lpage><pub-id pub-id-type="doi">10.1056/nejm199306243282503</pub-id><pub-id pub-id-type="other">2-s2.0-0027308989</pub-id><pub-id pub-id-type="pmid">8502269</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancefield</surname><given-names>R. C.</given-names></name></person-group><article-title>A serological differentiation of specific types of bovine hemolytic streptococci (group B)</article-title><source><italic>The Journal of Experimental Medicine</italic></source><year>1934</year><volume>59</volume><issue>4</issue><fpage>441</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1084/jem.59.4.441</pub-id><pub-id pub-id-type="pmid">19870257</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flores</surname><given-names>A. R.</given-names></name><name><surname>Galloway-Pe&#x000f1;a</surname><given-names>J.</given-names></name><name><surname>Sahasrabhojane</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Sequence type 1 group B <italic>Streptococcus</italic>, an emerging cause of invasive disease in adults, evolves by small genetic changes</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2015</year><volume>112</volume><issue>20</issue><fpage>6431</fpage><lpage>6436</lpage><pub-id pub-id-type="doi">10.1073/pnas.1504725112</pub-id><pub-id pub-id-type="pmid">25941374</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teatero</surname><given-names>S.</given-names></name><name><surname>McGeer</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Population structure and antimicrobial resistance of invasive serotype IV group B <italic>Streptococcus</italic>, Toronto, Ontario, Canada</article-title><source><italic>Emerging Infectious Diseases</italic></source><year>2015</year><volume>21</volume><issue>4</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.3201/eid2104.140759</pub-id><pub-id pub-id-type="other">2-s2.0-84924956579</pub-id><pub-id pub-id-type="pmid">25811284</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teatero</surname><given-names>S.</given-names></name><name><surname>Athey</surname><given-names>T. B. T.</given-names></name><name><surname>Van Caeseele</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Emergence of serotype IV group B <italic>Streptococcus</italic> adult invasive disease in Manitoba and Saskatchewan, Canada, is driven by clonal sequence type 459 strains</article-title><source><italic>Journal of Clinical Microbiology</italic></source><year>2015</year><volume>53</volume><issue>9</issue><fpage>2919</fpage><lpage>2926</lpage><pub-id pub-id-type="doi">10.1128/jcm.01128-15</pub-id><pub-id pub-id-type="other">2-s2.0-84940055944</pub-id><pub-id pub-id-type="pmid">26135871</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahesh</surname><given-names>S.</given-names></name><name><surname>Hensler</surname><given-names>M. E.</given-names></name><name><surname>Van Sorge</surname><given-names>N. M.</given-names></name><etal/></person-group><article-title>Point mutation in the group B streptococcal <italic>pbp2x</italic> gene conferring decreased susceptibility to <italic>&#x003b2;</italic>-lactam antibiotics</article-title><source><italic>Antimicrobial Agents and Chemotherapy</italic></source><year>2008</year><volume>52</volume><issue>8</issue><fpage>2915</fpage><lpage>2918</lpage><pub-id pub-id-type="doi">10.1128/aac.00461-08</pub-id><pub-id pub-id-type="other">2-s2.0-48749093934</pub-id><pub-id pub-id-type="pmid">18541727</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>S.</given-names></name><name><surname>Wachino</surname><given-names>J.-I.</given-names></name><etal/></person-group><article-title>First molecular characterization of group B streptococci with reduced penicillin susceptibility</article-title><source><italic>Antimicrobial Agents and Chemotherapy</italic></source><year>2008</year><volume>52</volume><issue>8</issue><fpage>2890</fpage><lpage>2897</lpage><pub-id pub-id-type="doi">10.1128/AAC.00185-08</pub-id><pub-id pub-id-type="other">2-s2.0-48749117985</pub-id><pub-id pub-id-type="pmid">18490507</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S. N.</given-names></name><name><surname>McGeer</surname><given-names>A.</given-names></name><name><surname>Melano</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Susceptibility of <italic>Streptococcus pneumoniae</italic> to fluoroquinolones in Canada</article-title><source><italic>Antimicrobial Agents and Chemotherapy</italic></source><year>2011</year><volume>55</volume><issue>8</issue><fpage>3703</fpage><lpage>3708</lpage><pub-id pub-id-type="doi">10.1128/aac.00237-11</pub-id><pub-id pub-id-type="other">2-s2.0-79960336110</pub-id><pub-id pub-id-type="pmid">21628545</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tazi</surname><given-names>A.</given-names></name><name><surname>Gueudet</surname><given-names>T.</given-names></name><name><surname>Varon</surname><given-names>E.</given-names></name><name><surname>Gilly</surname><given-names>L.</given-names></name><name><surname>Trieu-Cuot</surname><given-names>P.</given-names></name><name><surname>Poyart</surname><given-names>C.</given-names></name></person-group><article-title>Fluoroquinolone-resistant group B streptococci in acute exacerbation of chronic bronchitis</article-title><source><italic>Emerging Infectious Diseases</italic></source><year>2008</year><volume>14</volume><issue>2</issue><fpage>349</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.3201/eid1402.071006</pub-id><pub-id pub-id-type="other">2-s2.0-38949177054</pub-id><pub-id pub-id-type="pmid">18258143</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>Y.</given-names></name><name><surname>Fujiwara</surname><given-names>H.</given-names></name><name><surname>Mishima</surname><given-names>N.</given-names></name><etal/></person-group><article-title>First <italic>Streptococcus agalactiae</italic> isolates highly resistant to quinolones, with point mutations in <italic>gyrA</italic> and <italic>parC</italic>
</article-title><source><italic>Antimicrobial Agents and Chemotherapy</italic></source><year>2003</year><volume>47</volume><issue>11</issue><fpage>3605</fpage><lpage>3609</lpage><pub-id pub-id-type="doi">10.1128/aac.47.11.3605-3609.2003</pub-id><pub-id pub-id-type="other">2-s2.0-0242290940</pub-id><pub-id pub-id-type="pmid">14576126</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biedenbach</surname><given-names>D. J.</given-names></name><name><surname>Toleman</surname><given-names>M. A.</given-names></name><name><surname>Walsh</surname><given-names>T. R.</given-names></name><name><surname>Jones</surname><given-names>R. N.</given-names></name></person-group><article-title>Characterization of fluoroquinolone-resistant <italic>&#x003b2;</italic>-hemolytic <italic>Streptococcus</italic> spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997&#x02013;2004)</article-title><source><italic>Diagnostic Microbiology and Infectious Disease</italic></source><year>2006</year><volume>55</volume><issue>2</issue><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2005.12.006</pub-id><pub-id pub-id-type="other">2-s2.0-33646911368</pub-id><pub-id pub-id-type="pmid">16530373</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccinelli</surname><given-names>G.</given-names></name><name><surname>Gargiulo</surname><given-names>F.</given-names></name><name><surname>Corbellini</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Emergence of the first levofloxacin-resistant strains of <italic>Streptococcus agalactiae</italic> isolated in Italy</article-title><source><italic>Antimicrobial Agents and Chemotherapy</italic></source><year>2015</year><volume>59</volume><issue>4</issue><fpage>2466</fpage><lpage>2469</lpage><pub-id pub-id-type="doi">10.1128/aac.05127-14</pub-id><pub-id pub-id-type="other">2-s2.0-84949117646</pub-id><pub-id pub-id-type="pmid">25666148</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zankari</surname><given-names>E.</given-names></name><name><surname>Hasman</surname><given-names>H.</given-names></name><name><surname>Kaas</surname><given-names>R. S.</given-names></name><etal/></person-group><article-title>Genotyping using whole-genome sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testing</article-title><source><italic>The Journal of Antimicrobial Chemotherapy</italic></source><year>2013</year><volume>68</volume><issue>4</issue><fpage>771</fpage><lpage>777</lpage><pub-id pub-id-type="publisher-id">dks496</pub-id><pub-id pub-id-type="doi">10.1093/jac/dks496</pub-id><pub-id pub-id-type="other">2-s2.0-84875265483</pub-id><pub-id pub-id-type="pmid">23233485</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inouye</surname><given-names>M.</given-names></name><name><surname>Dashnow</surname><given-names>H.</given-names></name><name><surname>Raven</surname><given-names>L.-A.</given-names></name><etal/></person-group><article-title>SRST2: rapid genomic surveillance for public health and hospital microbiology labs</article-title><source><italic>Genome Medicine</italic></source><year>2014</year><volume>6</volume><issue>11, article 90</issue><pub-id pub-id-type="doi">10.1186/s13073-014-0090-6</pub-id><pub-id pub-id-type="other">2-s2.0-84928040686</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>D. C.</given-names></name><name><surname>Jacoby</surname><given-names>G. A.</given-names></name></person-group><article-title>Mechanisms of drug resistance: quinolone resistance</article-title><source><italic>Annals of the New York Academy of Sciences</italic></source><year>2015</year><volume>1354</volume><issue>1</issue><fpage>12</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1111/nyas.12830</pub-id><pub-id pub-id-type="other">2-s2.0-84945444280</pub-id><pub-id pub-id-type="pmid">26190223</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="book"><collab>Clinical and Laboratory Standards Institute</collab><article-title>Performance standards for antimicrobial susceptibility testing. 24th informational supplement</article-title><year>2014</year><issue>M100&#x02013;S24</issue><publisher-loc>Wayne, Pa, USA</publisher-loc><publisher-name>Clinical and Laboratory Standards Institute</publisher-name></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>T. N.</given-names></name><name><surname>Srinivasan</surname><given-names>U.</given-names></name><name><surname>Britt</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Efflux-mediated resistance identified among norfloxacin resistant clinical strains of group B <italic>Streptococcus</italic> from South Korea</article-title><source><italic>Epidemiology and Health</italic></source><year>2014</year><volume>36</volume><pub-id pub-id-type="publisher-id">e2014022</pub-id><pub-id pub-id-type="doi">10.4178/epih/e2014022</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusbaum</surname><given-names>C.</given-names></name><name><surname>Ohsumi</surname><given-names>T. K.</given-names></name><name><surname>Gomez</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Sensitive, specific polymorphism discovery in bacteria using massively parallel sequencing</article-title><source><italic>Nature Methods</italic></source><year>2009</year><volume>6</volume><issue>1</issue><fpage>67</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1286</pub-id><pub-id pub-id-type="other">2-s2.0-58149215803</pub-id><pub-id pub-id-type="pmid">19079253</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tritt</surname><given-names>A.</given-names></name><name><surname>Eisen</surname><given-names>J. A.</given-names></name><name><surname>Facciotti</surname><given-names>M. T.</given-names></name><name><surname>Darling</surname><given-names>A. E.</given-names></name></person-group><article-title>An integrated pipeline for <italic>de novo</italic> assembly of microbial genomes</article-title><source><italic>PLoS ONE</italic></source><year>2012</year><volume>7</volume><issue>9</issue><pub-id pub-id-type="publisher-id">e42304</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0042304</pub-id><pub-id pub-id-type="other">2-s2.0-84866391549</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>M. J.</given-names></name><name><surname>Brenwald</surname><given-names>N. P.</given-names></name><name><surname>Wise</surname><given-names>R.</given-names></name></person-group><article-title>Identification of an efflux pump gene, <italic>pmrA</italic>, associated with fluoroquinolone resistance in<italic> Streptococcus pneumoniae</italic>
</article-title><source><italic>Antimicrobial Agents and Chemotherapy</italic></source><year>1999</year><volume>43</volume><issue>1</issue><fpage>187</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1093/jac/43.2.187</pub-id><pub-id pub-id-type="other">2-s2.0-0032907704</pub-id><pub-id pub-id-type="pmid">9869592</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clonal complex 1 group B <italic>Streptococcus</italic> strains used in this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Age group<sup>a</sup>
</th><th rowspan="2" align="center" colspan="1">Sequence type</th><th rowspan="2" align="center" colspan="1">Number of strains</th><th colspan="3" align="center" rowspan="1">Source of isolation</th><th colspan="6" align="center" rowspan="1">Year of isolation</th><th colspan="3" align="center" rowspan="1">Macrolide resistance gene</th><th align="center" rowspan="1" colspan="1">Tetracycline resistance gene</th></tr><tr><th align="center" rowspan="1" colspan="1">Blood</th><th align="center" rowspan="1" colspan="1">Joint fluid</th><th align="center" rowspan="1" colspan="1">Other<sup>b</sup>
</th><th align="center" rowspan="1" colspan="1">2009</th><th align="center" rowspan="1" colspan="1">2010</th><th align="center" rowspan="1" colspan="1">2011</th><th align="center" rowspan="1" colspan="1">2012</th><th align="center" rowspan="1" colspan="1">2013</th><th align="center" rowspan="1" colspan="1">2014</th><th align="left" rowspan="1" colspan="1">
<italic>ermTR</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>ermB</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>mefA</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>tetM</italic>
</th></tr></thead><tbody><tr><td rowspan="2" align="left" colspan="1">EOD (<italic>n</italic> = 6)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="center" colspan="16" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">LOD (<italic>n</italic> = 1)</td><td align="center" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" colspan="16" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Child (<italic>n</italic> = 3)</td><td align="center" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="center" colspan="16" rowspan="1">
<hr/>
</td></tr><tr><td rowspan="2" align="left" colspan="1">Adult (<italic>n</italic> = 74)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="center" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">48</td></tr><tr><td align="center" colspan="16" rowspan="1">
<hr/>
</td></tr><tr><td rowspan="2" align="left" colspan="1">Older adult (<italic>n</italic> = 106)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">51</td></tr><tr><td align="center" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">37</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a</sup>Isolates were collected from neonates with early onset disease (EOD) (less than 7 days of age); infants with late onset disease (LOD) (7 to 90 days of age); children (aged more than 90 days to 18 years); adults (19 years to 59 years); and older adults (more than 60 years of age).</p></fn><fn><p>
<sup>b</sup>Samples collected from normally sterile sites other than blood or synovial fluid.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Characteristics of mutations observed in GyrA, GyrB, ParC, and ParE among ST459 and ST1 group B <italic>Streptococcus</italic> isolates used in this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">ST</th><th rowspan="2" align="center" colspan="1">Number of isolates</th><th colspan="4" align="center" rowspan="1">&#x02009;Predicted amino acid substitution</th><th colspan="3" align="center" rowspan="1">Antibiotic<sup>a</sup>
</th><th colspan="3" align="center" rowspan="1">MIC (mg/L)</th><th rowspan="2" align="center" colspan="1">Year</th><th rowspan="2" align="center" colspan="1">Reference</th></tr><tr><th align="center" rowspan="1" colspan="1"> GyrB</th><th align="center" rowspan="1" colspan="1"> GyrA</th><th align="center" rowspan="1" colspan="1"> ParC</th><th align="center" rowspan="1" colspan="1"> ParE</th><th align="center" rowspan="1" colspan="1">LVX</th><th align="center" rowspan="1" colspan="1">NOR</th><th align="center" rowspan="1" colspan="1">CIP</th><th align="center" rowspan="1" colspan="1">LVX</th><th align="center" rowspan="1" colspan="1">NOR</th><th align="center" rowspan="1" colspan="1">CIP</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">E85K</td><td align="center" rowspan="1" colspan="1">S79F</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">2010, 2012</td><td align="center" rowspan="1" colspan="1">[<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B10" ref-type="bibr">10</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">S81L</td><td align="center" rowspan="1" colspan="1">S79F</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1">[<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B9" ref-type="bibr">9</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">V79I</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">E224G</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">E566D</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2012</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">G717S</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">S79F</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">[<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">D83G, D806G</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1">[<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B10" ref-type="bibr">10</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">R449S</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">Q444K</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">A218T</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2012</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">S412L</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2012</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">R474H</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2010, 2012</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">D83V</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2012</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">D83Y</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2012</td><td align="center" rowspan="1" colspan="1">[<xref rid="B10" ref-type="bibr">10</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">S79F</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2011</td><td align="center" rowspan="1" colspan="1">[<xref rid="B7" ref-type="bibr">7</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">V627I</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2010</td><td align="center" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">459</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">V206I</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">NS</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2012</td><td align="center" rowspan="1" colspan="1">This study</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a</sup>R: resistant, S: susceptible, I: intermediate resistance, and NS: increased MIC. For levofloxacin (LVX), MIC of &#x02265;8&#x02009;mg/L: resistant, 4&#x02009;mg/L: intermediate resistant, and &#x02264;2&#x02009;mg/L: susceptible. For norfloxacin (NOR), MIC of &#x02265;4&#x02009;mg/L: resistant; &#x02264;1&#x02009;mg/L: susceptible. For ciprofloxacin (CIP), MIC of &#x0003e;2&#x02009;mg/L: resistant; &#x02264;0.125: susceptible. Values which were in the range of 0.125 to 2 were considered as having reduced susceptibility (NS).</p></fn></table-wrap-foot></table-wrap></floats-group></article>